[go: up one dir, main page]

MX2017011935A - Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2). - Google Patents

Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2).

Info

Publication number
MX2017011935A
MX2017011935A MX2017011935A MX2017011935A MX2017011935A MX 2017011935 A MX2017011935 A MX 2017011935A MX 2017011935 A MX2017011935 A MX 2017011935A MX 2017011935 A MX2017011935 A MX 2017011935A MX 2017011935 A MX2017011935 A MX 2017011935A
Authority
MX
Mexico
Prior art keywords
disease
triazolyl
compounds
parkinson
pde2 inhibitors
Prior art date
Application number
MX2017011935A
Other languages
English (en)
Inventor
Troy Mccracken
Alejandro Crespo
Xu Shimin
Ming Shen Dong-
J Sinz Christopher
E Wilson Jonathan
Li Haitang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2017011935A publication Critical patent/MX2017011935A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se dirige a compuestos de pirimidina carboxamida de la fórmula I que son útiles como agentes terapéuticos para el tratamiento de trastornos del sistema nervioso central asociados con fosfodiesterasa 2 (PDE2); la presente invención también se refiere al uso de tales compuestos para tratar trastornos neurológicos y psiquiátricos, tales como esquizofrenia, psicosis, enfermedad de Parkinson, demencia de la enfermedad de Parkinson (PDD), o enfermedad de Huntington, y esos asociados con la hipofunción del estriado o disfunción del ganglio basal. (ver Fórmula).
MX2017011935A 2015-03-17 2016-03-11 Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2). MX2017011935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/074396 WO2016145614A1 (en) 2015-03-17 2015-03-17 Triazolyl pyrimidinone compounds as pde2 inhibitors
PCT/US2016/021902 WO2016149058A1 (en) 2015-03-17 2016-03-11 Triazolyl pyrimidinone compounds as pde2 inhibitors

Publications (1)

Publication Number Publication Date
MX2017011935A true MX2017011935A (es) 2018-02-09

Family

ID=56919578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011935A MX2017011935A (es) 2015-03-17 2016-03-11 Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2).

Country Status (11)

Country Link
US (1) US10358435B2 (es)
EP (1) EP3270926B1 (es)
JP (1) JP2018508542A (es)
KR (1) KR20170123697A (es)
CN (1) CN107530343A (es)
AU (1) AU2016233618A1 (es)
BR (1) BR112017019685A2 (es)
CA (1) CA2979222A1 (es)
MX (1) MX2017011935A (es)
RU (1) RU2017134107A (es)
WO (2) WO2016145614A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179059A1 (en) * 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
HK1256751A1 (zh) 2015-11-02 2019-10-04 Janssen Pharmaceutica Nv [1，2，4]三唑并[1，5-a]嘧啶-7-基化合物
ES2912264T3 (es) 2016-11-02 2022-05-25 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
EA039102B1 (ru) 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
TWI764950B (zh) 2016-11-02 2022-05-21 比利時商健生藥品公司 Ｐｄｅ２抑制劑
AU2019297361B2 (en) * 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US20210330736A1 (en) * 2018-09-05 2021-10-28 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
CN109678848B (zh) * 2018-12-29 2020-10-09 浙江工业大学 香豆素/吡啶酮杂合衍生物及其制备方法与应用
CN114890897A (zh) * 2022-05-31 2022-08-12 常州大学 一种pde2抑制剂内酯类衍生物及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299633B6 (cs) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
IL139456A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
EP1395590B1 (en) 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists
EP1441735B1 (en) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
DE10328479A1 (de) * 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
AP2006003632A0 (en) 2003-12-16 2006-06-30 Pfizer Prod Inc Pyridol[2,3-D] pyrimidine-2,4-Diamines as PDE 2 inhibitors
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
DE602005021894D1 (de) 2004-09-02 2010-07-29 Nycomed Gmbh Triazolophthalazine
KR20070095986A (ko) * 2005-01-05 2007-10-01 니코메드 게엠베하 Ｐｄｅ2 억제제로서의 트리아졸로프탈라진
WO2007058646A1 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors: cyclic pyrimidinone compounds
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2010535192A (ja) 2007-08-02 2010-11-18 ファイザー・インク ピリミジンおよびピリジン誘導体ならびにその薬学的な使用および組成物
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2009321601B2 (en) * 2008-12-04 2012-11-01 F. Hoffmann-La Roche Ag Pyridazinone derivatives
ES2602902T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
WO2011011312A1 (en) 2009-07-22 2011-01-27 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
PH12013501556A1 (en) 2011-02-23 2017-10-25 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
MX2013014470A (es) 2011-06-07 2014-03-21 Pfizer Compuestos de pirazolo[3,4-d]pirimidina y su uso como inhibidores pde2 y/o inhibidores cyp3a4.
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EP2763989A1 (en) 2011-09-09 2014-08-13 H. Lundbeck A/S Pyridine compounds and uses thereof
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
EP2763533B1 (en) 2011-10-06 2021-12-29 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
US9266881B2 (en) * 2011-11-14 2016-02-23 Merck Sharp & Dohme Corp. Triazolopyridinone PDE10 inhibitors
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
SG11201406552UA (en) 2012-04-25 2014-11-27 Takeda Pharmaceutical Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
EP2919781B1 (en) * 2012-11-15 2017-06-28 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
WO2014139983A1 (en) 2013-03-13 2014-09-18 H. Lundbeck A/S [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
RU2017134107A (ru) 2019-04-05
KR20170123697A (ko) 2017-11-08
EP3270926B1 (en) 2021-08-04
CA2979222A1 (en) 2016-09-22
US20180237422A1 (en) 2018-08-23
EP3270926A4 (en) 2018-08-01
WO2016145614A1 (en) 2016-09-22
US10358435B2 (en) 2019-07-23
WO2016149058A1 (en) 2016-09-22
JP2018508542A (ja) 2018-03-29
EP3270926A1 (en) 2018-01-24
CN107530343A (zh) 2018-01-02
AU2016233618A1 (en) 2017-09-14
BR112017019685A2 (pt) 2018-05-15

Similar Documents

Publication Publication Date Title
MY157301A (en) Pyrimidine pde10 inhibitors
MX2017011935A (es) Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2).
WO2012044561A3 (en) 2-alkoxy pyrimidine pde10 inhibitors
MX2019014597A (es) Inhibidores de pirazolopirimidina de pde9.
WO2012044562A3 (en) Pyrazolopyrimidine pde10 inhibitors
MX2018005215A (es) Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-p iperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas.
MY193511A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
WO2012054366A3 (en) Substituted amino-triazolyl pde10 inhibitors
MX2015008860A (es) Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos.
MX2016012483A (es) Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.
MY199446A (en) Compounds and compositions and uses thereof
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
MX2017006049A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidro piridinas como inhibidores de bace1.
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
TN2019000175A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX390505B (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
MX369345B (es) Procesos para la preparacion de analogos de oxitocina.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX386174B (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2
WO2014150114A8 (en) Substituted pyridizinone derivatives as pde10 inhibitors
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
ZA202308795B (en) Pro drugs of pde10 compounds
ECSP14013268A (es) Inhibidores de pde10 de pirimidina
AR112073A1 (es) Inhibidores de pirazolopirimidina de pde9